Second-degree atrioventricular (AV) block represents a critical disruption in the electrical conduction system of the heart, where impulses from the atria fail to consistently reach the ventricles. This condition sits between the benign irregularity of first-degree block and the life-threatening complete heart block, demanding careful evaluation and precise management. Understanding the nuances of AV block 2 is essential for clinicians, as it directly impacts cardiac output and systemic perfusion.
Classification and Pathophysiology
The classification of second-degree AV block is primarily divided into two distinct types, Mobitz Type I and Mobitz Type II, each with unique electrophysiological mechanisms and clinical implications. The differentiation hinges on the behavior of the PR interval on the electrocardiogram (ECG) and the site of the conduction deficit within the His-Purkinje system. This structural distinction is not merely academic; it dictates the stability of the rhythm and the urgency of intervention.
Mobitz Type I (Wenckebach)
Mobitz Type I, also known as Wenckebach phenomenon, is characterized by a progressive lengthening of the PR interval until a P-wave is finally conducted and followed by a QRS complex. This cyclical pattern results from a decremental conduction within the AV node, where each successive impulse faces increasing resistance until one fails to traverse the threshold. This block is typically transient and often asymptomatic, frequently discovered incidentally during routine ECG monitoring or physical examinations.
Mobitz Type II
In contrast, Mobitz Type II presents with a constant PR interval preceding a non-conducted P wave, without the progressive prolongation seen in Wenckebach. This type indicates a block distal to the AV node, usually within the infrahisian conduction system, and is far more concerning due to its unpredictable progression to complete heart block. The sudden cessation of ventricular depolarization without warning signs makes this variant particularly dangerous and a stronger indicator for pacemaker implantation.
Clinical Manifestations and Diagnosis
Patients with second-degree AV block may remain entirely asymptomatic, with the condition identified only through standard ECG screening. However, when symptoms do occur, they are generally related to reduced cerebral perfusion and include dizziness, lightheadedness, syncope (fainting), or near-syncope. In more severe instances, individuals might experience chest pain or signs of heart failure, such as shortness of breath, due to the compromised cardiac output.
The diagnosis of AV block 2 is fundamentally reliant on the 12-lead ECG, which provides the definitive evidence of the conduction abnormality. Cardiologists meticulously analyze the PR interval regularity, the ratio of conducted to non-conducted P waves, and the width of the QRS complex. This analysis helps pinpoint the exact location of the block and guides the subsequent risk stratification, distinguishing between benign and high-risk presentations.
Risk Stratification and Management
Management strategies for second-degree AV block are not uniform and are primarily driven by the specific type, the presence of symptoms, and the underlying etiology. Asymptomatic Mobitz Type I blocks, particularly those occurring during sleep or in healthy athletes, may only require regular monitoring without immediate intervention. Conversely, symptomatic Mobitz Type II or any block associated with significant bradycardia often necessitates urgent evaluation for permanent pacemaker therapy to prevent progression to asystole.
It is crucial to address reversible causes that may exacerbate or even mimic second-degree AV block, such as electrolyte imbalances, pharmacological effects from beta-blockers or calcium channel blockers, or acute myocardial ischemia. A thorough review of medications and correction of metabolic derangements can sometimes resolve the conduction issue, avoiding the need for invasive device implantation. The decision to proceed with a pacemaker is a collaborative one, balancing the risks of sudden cardiac events against the procedural risks of device implantation.
